Leland Stanford Junior University

Auransa Inc.

Sct Ii LLC

Sct Incorporated

Khloris Biosciences, Inc.

Joseph C Wu

Michael T Longaker

Mark A Kay

Irving L Weissman

Sanjiv Sam Gambhir

Pek Yee Lum

Zhong Zhong

Sidney Paul Elmer

Guanyi Huang

Viwat Visuthikraisee

Eithon Michael G Cadag

Thomas Bernard Freeman

Christopher G Armstrong

Kevin J Kim

Lisa Maria Lucia Pham

Eunhye Park

Zhi-Ying Chen

Robert C Robbins

Mei Huang

Andrew Stephen Lee

Paul W Burridge

Mark M Davis

Amato J Giaccia

Divya Nag

Edwin Chang

Lynne Bui

Denise Chan

Charles K F Chan

Ning Sung

FangJun Jia

Eun Young Seo

Nicholas Panetta

Deepak Gupta

Mirwais Wardak

Nigel G Kooreman

Jeremy Pearl

Ning Sun

Feng Lan

This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3',4&#x2032;,5&#x2032;-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Methods, compositions, and kits for producing functional blood vessels, and progenitors thereof are provided. Human disorders of the vascular system are treated by reconstitution of functional vessels in vivo through co-transplantation with supporting niche stromal cells for treatment of ischemic injury in the peripheral limbs and heart. The cell populations of the invention, when engrafted into a recipient, anastomose with host vasculature and regenerate functional blood vessels.

Identification and uses of vasculature forming progenitor cells and progenitor cell combinations

In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.

IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer

Compositions and methods are provided for transplantation of pluripotent stem cells and differentiated cells derived therefrom.

Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade

Human somatic cells obtained from individuals with a genetic heart condition are reprogrammed to become induced pluripotent stem cells (iPS cells), and differentiated into cardiomyocytes for use in analysis, screening programs, and the like.

Cardiomyocytes from induced pluripotent stem cells from patients and methods of use thereof

Methods are provided for producing a cardiomyocyte population from a mammalian pluripotent stem cell population. Aspects of the methods include using a Wnt signaling agonist and antagonist, each in minimal media, to modulate Wnt signaling. Also provided are kits for practicing the methods described herein.

Chemically defined production of cardiomyocytes from pluripotent stem cells

Human somatic cells are reprogrammed to become induced pluripotent stem cells (iPS cells) by the introduction of a minicircle DNA vector. Cells of interest include adipose stem cells.

Method of making induced pluripotent stem cell from adipose stem cells using minicircle DNA vectors

Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor&#x2014;lot (HIF-1 &#x3b1;) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1&#x3b1; and asparaginyl hydroxylase genes. The vectors encoding shRNA are also useful for the treatment of cardiac diseases, peripheral vascular diseases and decubitis ulcers.

ShRNA gene therapy for treatment of ischemic heart disease

Compositions and methods are provided for the treatment of an ischemic cardiovascular condition by providing a patient with a novel non-viral minicircle DNA vector comprising polynucleotide sequences that potentiate HIF-1 activity, including RNAi or antisense agents selective for proteins involved in HIF1 inactivation.

Use on minicircle vectors for cardiac gene therapy

Growing community of inventors

Palo Alto, CA, United States of America

Joseph C Wu